SCHEMBL248163

SCHEMBL248163

COCC(=O)Oc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.50
CYP19A1 P11511 1/20 0.49
ELANE P08246 1/20 0.49
LMNA P02545 3/20 0.48
KMT2A Q03164 3/20 0.48
ALDH1A1 P00352 3/20 0.48
MAPT P10636 3/20 0.48
HTT P42858 2/20 0.48
HSD17B10 Q99714 1/20 0.48
PDGFRB P09619 1/20 0.48
PDGFRA P16234 1/20 0.48
ALOX15 P16050 1/20 0.47
PRSS1 P07477 1/20 0.46
PRSS2 P07478 1/20 0.46
PRSS3 P35030 1/20 0.46
TSHR P16473 1/20 0.44
HPGD P15428 2/20 0.44
MEN1 O00255 1/20 0.44
CYP2C19 P33261 1/20 0.43
ALOX12 P18054 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5696642 0.89 KMT2A (0.59) GAAELANELMNAKMT2AALDH1A1
SCHEMBL11595637 0.85 GAA (0.45) GAACYP19A1ELANELMNAKMT2A
SCHEMBL13842309 0.84 GAA (0.47) GAACYP19A1ELANELMNAKMT2A
SCHEMBL16326823 0.83 ALDH1A1 (0.46) GAACYP19A1ELANELMNAKMT2A
SCHEMBL28001930 0.83 ALDH1A1 (0.55) GAACYP19A1ELANELMNAKMT2A
SCHEMBL18087017 0.83 LMNA (0.53) GAAELANELMNAKMT2AALDH1A1
SCHEMBL27283394 0.83 LMNA (0.66) GAALMNAKMT2AALDH1A1MAPT
SCHEMBL11437247 0.83 CYP19A1 (0.52) GAACYP19A1ELANELMNAKMT2A
SCHEMBL472034 0.81 ALOX15 (0.65) GAACYP19A1LMNAKMT2AALDH1A1
SCHEMBL27837444 0.81 CYP19A1 (0.50) GAACYP19A1ELANELMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140350301-A1 NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR ACTAVIS GROUP PTC EHF (IS) 2014-11-27 US claimed
US-20130165696-A1 NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR ACTAVIS GROUP PTC EHF (IS) 2013-06-27 US claimed
EP-0425650-A1 ANTI-INFLAMMATORY 4-AMINOPHENOL DERIVATIVES. FISONS PLC (GB) 1991-05-08 EP claimed
WO-1990014338-A1 ANTI-INFLAMMATORY 4-AMINOPHENOL DERIVATIVES FISONS PLC (GB) 1990-11-29 WO claimed
CN-115746003-B Methods of making and using PDE9 inhibitors 卡都瑞恩医药公司 2024-08-09 CN disclosed
US-20240254366-A1 POLISHING COMPOSITION, POLISHING METHOD, AND METHOD OF MANUFACTURING SEMICONDUCTOR SUBSTRATE FUJIMI INCORPORATED (JP) 2024-08-01 US disclosed
EP-4284854-A1 REPROCESSABLE COMPOSITIONS Massachusetts Institute of Technology (US) 2023-12-06 EP disclosed
EP-3406684-B1 POLISHING COMPOSITION AND METHOD FOR POLISHING SILICON SUBSTRATE FUJIMI INC (JP) 2023-09-06 EP disclosed
US-11702570-B2 Polishing composition FUJIMI INCORPORATED (JP) 2023-07-18 US disclosed
US-11695155-B2 Non-aqueous electrolytic solution and non-aqueous electrolyte secondary battery using the same MITSUBISHI CHEMICAL CORPORATION (JP) 2023-07-04 US disclosed
US-20230155178-A1 NON-AQUEOUS ELECTROLYTIC SOLUTION AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY USING THE SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2023-05-18 US disclosed
WO-2022256480-A1 ARYLCOUMARIN SYNTHESIS WITH AZEOTROPIC REMOVAL OF WATER CONAGEN INC. (US) 2022-12-08 WO disclosed
EP-0394101-B1 Benzothiazepine derivatives, process for their preparation and thereby obtained intermediates, their use as medicines and compositions containing them ROUSSEL UCLAF (FR) 1994-08-24 EP disclosed
EP-0578473-A1 Catalyst for polymerization of olefin and process for producing olefin polymer SHOWA DENKO KABUSHIKI KAISHA (JP) 1994-01-12 EP disclosed
US-5041403-A Magnesium, titanium, halogen, ester compound, and organic aluminum compound SHOWA DENKO K.K. (JP) 1991-08-20 US disclosed
EP-0394101-A1 Benzothiazepine derivatives, process for their preparation and thereby obtained intermediates, their use as medicines and compositions containing them ROUSSEL-UCLAF (FR) 1990-10-24 EP disclosed
EP-0383346-A2 Catalyst, process for its preparation and process for polymerization of olefins using this catalyst SHOWA DENKO KABUSHIKI KAISHA (JP) 1990-08-22 EP disclosed
EP-0098743-B1 PHENYL ALPHA-ACYLOXYACETAMIDE DERIVATES AND THEIR THERAPEUTIC USE Yu, Ruey J., Dr. (US) 1988-09-28 EP disclosed
EP-0098743-A1 Phenyl alpha-acyloxyacetamide derivates and their therapeutic use Yu, Ruey J., Dr. (US) 1984-01-18 EP disclosed
US-4040992-A USING N-HYDROXYALKYL QUATERNARY AMMONIUM CARBONYLATE SALTS AS CATALYSTS; POLYURETHANES, POLYISOCYANURATES AIR PRODUCTS AND CHEMICALS, INC. (US) 1977-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11695155-B2 Non-aqueous electrolytic solution and non-aqueous electrolyte secondary battery using the same PTPN1, TP53RK, VDAC1 GAA 3551/4885CYP19A1 1192/4885ELANE 869/4885
US-20140350301-A1 NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR THPO, P2RY4, TBXA2R GAA 1682/4885CYP19A1 3235/4885ELANE 4586/4885
US-20230155178-A1 NON-AQUEOUS ELECTROLYTIC SOLUTION AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY USING THE SAME PTPN1, TP53RK, VDAC1 GAA 3551/4885CYP19A1 1192/4885ELANE 869/4885
US-20130165696-A1 NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR THPO, P2RY4, TBXA2R GAA 1682/4885CYP19A1 3235/4885ELANE 4586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.